These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 29061086)

  • 1. Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients.
    Rungtivasuwan K; Avihingsanon A; Thammajaruk N; Mitruk S; Burger DM; Ruxrungtham K; Sukasem C; Punyawudho B
    Pharmacogenomics; 2017 Nov; 18(16):1481-1490. PubMed ID: 29061086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patients.
    Rungtivasuwan K; Avihingsanon A; Thammajaruk N; Mitruk S; Burger DM; Ruxrungtham K; Punyawudho B; Pengsuparp T
    Antimicrob Agents Chemother; 2015; 59(6):3240-5. PubMed ID: 25801567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Single-Nucleotide Polymorphism in ABCC4 Is Associated with Tenofovir-Related Beta2-Microglobulinuria in Thai Patients with HIV-1 Infection.
    Likanonsakul S; Suntisuklappon B; Nitiyanontakij R; Prasithsirikul W; Nakayama EE; Shioda T; Sangsajja C
    PLoS One; 2016; 11(1):e0147724. PubMed ID: 26807589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of tenofovir in HIV/HBV co-infected patients.
    Punyawudho B; Thammajaruk N; Thongpeang P; Matthews G; Lewin SR; Burger D; Ruxrungtham K; Avihingsanon A
    Int J Clin Pharmacol Ther; 2015 Nov; 53(11):947-54. PubMed ID: 26308175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial.
    Dickinson L; Gurjar R; Stöhr W; Bonora S; Owen A; D'Avolio A; Cursley A; Molina JM; Fäetkenheuer G; Vandekerckhove L; Di Perri G; Pozniak A; Richert L; Raffi F; Boffito M;
    J Antimicrob Chemother; 2020 Mar; 75(3):628-639. PubMed ID: 31754703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients.
    Kiser JJ; Carten ML; Aquilante CL; Anderson PL; Wolfe P; King TM; Delahunty T; Bushman LR; Fletcher CV
    Clin Pharmacol Ther; 2008 Feb; 83(2):265-72. PubMed ID: 17597712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ABCC2*1C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen.
    Manosuthi W; Sukasem C; Thongyen S; Nilkamhang S; Sungkanuparph S
    J Antimicrob Chemother; 2014 Aug; 69(8):2195-201. PubMed ID: 24788661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal function in HIV/HBV co-infected and HBV mono-infected patients on a long-term treatment with tenofovir in real life setting.
    Milazzo L; Gervasoni C; Falvella FS; Cattaneo D; Mazzali C; Ronzi P; Binda F; Cheli S; Sollima S; Antinori S
    Clin Exp Pharmacol Physiol; 2017 Feb; 44(2):191-196. PubMed ID: 27809359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal function of participants in the Bangkok tenofovir study--Thailand, 2005-2012.
    Martin M; Vanichseni S; Suntharasamai P; Sangkum U; Mock PA; Gvetadze RJ; Curlin ME; Leethochawalit M; Chiamwongpaet S; Cherdtrakulkiat T; Anekvorapong R; Leelawiwat W; Chantharojwong N; McNicholl JM; Paxton LA; Kittimunkong S; Choopanya K;
    Clin Infect Dis; 2014 Sep; 59(5):716-24. PubMed ID: 24829212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients.
    Kiser JJ; Aquilante CL; Anderson PL; King TM; Carten ML; Fletcher CV
    J Acquir Immune Defic Syndr; 2008 Mar; 47(3):298-303. PubMed ID: 18398970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals.
    Aouri M; Barcelo C; Guidi M; Rotger M; Cavassini M; Hizrel C; Buclin T; Decosterd LA; Csajka C;
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open-label pilot study to determine the efficacy of lopinavir/ritonavir and tenofovir DF in the treatment of HIV-infected patients experiencing first virologic failure on a non-nucleoside-based regimen.
    Pierone G; Mieras J; Bulgin-Coleman D; Kantor C; Shearer J; Fontaine L; Fath M
    AIDS Patient Care STDS; 2008 Apr; 22(4):263-6. PubMed ID: 18422459
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacogenetics-based population pharmacokinetic analysis for dose optimization of ritonavir-boosted atazanavir in Thai adult HIV-infected patients.
    Singkham N; Avihingsanon A; Brundage RC; Birnbaum AK; Thammajaruk N; Ruxrungtham K; Bunupuradah T; Kiertiburanakul S; Chetchotisakd P; Punyawudho B;
    Expert Rev Clin Pharmacol; 2022 Jan; 15(1):99-108. PubMed ID: 34727835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Concomitant Antiretrovirals and CYP2C9/CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine.
    Green B; Crauwels H; Kakuda TN; Vanveggel S; Brochot A
    Clin Pharmacokinet; 2017 May; 56(5):525-536. PubMed ID: 27665573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.
    von Hentig N; Dauer B; Haberl A; Klauke S; Lutz T; Staszewski S; Harder S
    Eur J Clin Pharmacol; 2007 Oct; 63(10):935-40. PubMed ID: 17665183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lopinavir and tenofovir interaction observed in non-pregnant adults altered during pregnancy.
    Mulligan N; Salama E; Momper JD; Capparelli EV; Stek A; Chakhtoura N; Mirochnick M; Best BM;
    J Clin Pharm Ther; 2021 Oct; 46(5):1459-1464. PubMed ID: 34254323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Administration of tenofovir disoproxil fumarate-based antiretroviral therapy in an HIV-infected patient following unilateral nephrectomy.
    Biagi M; Badowski M; Chiampas T; Young J; Vaughn P; Shicker L; Patel M
    Int J STD AIDS; 2016 Aug; 27(9):808-11. PubMed ID: 26378193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.
    Lubomirov R; di Iulio J; Fayet A; Colombo S; Martinez R; Marzolini C; Furrer H; Vernazza P; Calmy A; Cavassini M; Ledergerber B; Rentsch K; Descombes P; Buclin T; Decosterd LA; Csajka C; Telenti A;
    Pharmacogenet Genomics; 2010 Apr; 20(4):217-30. PubMed ID: 20139798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study.
    Pedrol E; Caro-Murillo AM; Castaño MA; Riera M; Olalla J; Domingo P; Arazo P; Gómez-Sirvent JL; Pulido F; Romero-Palacios A; Aguirrebengoa K; Vera F; Ferrer P; Blanco Ramos JR
    HIV Clin Trials; 2015; 16(1):43-8. PubMed ID: 25777189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.